Decision support systems for incurable non-small cell lung cancer: a systematic review

BackgroundIndividually tailored cancer treatment is essential to ensure optimal treatment and resource use. Treatments for incurable metastatic non-small cell lung cancer (NSCLC) are evolving rapidly, and decision support systems (DSS) for this patient population have been developed to balance benefits and harms for decision-making. The aim of this systematic review was to inventory DSS for stage IIIB/IV NSCLC patients.MethodsA systematic literature search was performed in Pubmed, Embase and the Cochrane Library. DSS were described extensively, including their predictors, model performances (i.e., discriminative ability and calibration), levels of validation and user friendliness.ResultsThe systematic search yielded 3531 articles. In total, 67 articles were included after additional reference tracking. The 39 identified DSS aim to predict overall survival and/or progression-free survival, but give no information about toxicity or cost-effectiveness. Various predictors were incorporated, such as performance status, serum and inflammatory markers, and patient and tumor characteristics. Some DSS were developed for the entire incurable NSCLC population, whereas others were specifically for patients with brain or spinal metastases. Few DSS had been validated externally using recent clinical data, and the discrimination and calibration were often poor.ConclusionsMany DSS have been developed for incurable NSCLC patients, but DSS are still lacking that are up-to-date with a good model performance, while covering the entire treatment spectrum. Future DSS should incorporate genetic and biological markers based on state-of-the-art evidence, and compare multiple treatment options to estimate survival, toxicity and cost-effectiveness.

[1]  A. Nicholson,et al.  Non-small-cell lung cancer , 2011, The Lancet.

[2]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[3]  K. Silay,et al.  A Laboratory Prognostic Index Model for Patients with Advanced Non-Small Cell Lung Cancer , 2014, PloS one.

[4]  L. Tang,et al.  Accuracy of Tokuhashi score system in predicting survival of lung cancer patients with vertebral metastasis , 2015, Journal of Neuro-Oncology.

[5]  Yvonne Vergouwe,et al.  A calibration hierarchy for risk models was defined: from utopia to empirical data. , 2016, Journal of clinical epidemiology.

[6]  C. Gridelli,et al.  Prognostic score for second-line chemotherapy of advanced non-small-cell lung cancer: external validation in a phase III trial comparing vinflunine with docetaxel. , 2012, Lung cancer.

[7]  Walter Curran,et al.  A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. , 2008, International journal of radiation oncology, biology, physics.

[8]  William Pao,et al.  CUSTOM-SEQ: a prototype for oncology rapid learning in a comprehensive EHR environment , 2016, J. Am. Medical Informatics Assoc..

[9]  Yaping Tian,et al.  Development and cross-validation of prognostic models to assess the treatment effect of cisplatin/pemetrexed chemotherapy in lung adenocarcinoma patients , 2014, Medical Oncology.

[10]  C. Gridelli,et al.  Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  R. Bremnes,et al.  Prognostic Scores in Patients with Brain Metastases from Non-small Cell Lung Cancer , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  Y. Tokuhashi,et al.  Outcome of Treatment for Spinal Metastases Using Scoring System for Preoperative Evaluation of Prognosis , 2009, Spine.

[13]  Hong‐Lin Chen,et al.  Comparison of Glasgow prognostic score and prognostic index in patients with advanced non-small cell lung cancer , 2015, Journal of Cancer Research and Clinical Oncology.

[14]  M. McDermott,et al.  Prognostic factors and grading systems for overall survival in patients treated with radiosurgery for brain metastases: variation by primary site. , 2008, Journal of neurosurgery.

[15]  K. McGlynn,et al.  A Prognostic Model to Predict Mortality among Non–Small-Cell Lung Cancer Patients in the U.S. Military Health System , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  R. Shi,et al.  Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review , 2013, BMC Cancer.

[17]  P. Krawczyk,et al.  The Applicability of a Predictive Index for Second- and Third-Line Treatment of Unselected Non-Small-Cell Lung Cancer Patients , 2011, Respiration.

[18]  P. Brown,et al.  Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. , 2009, International journal of radiation oncology, biology, physics.

[19]  B. Levy,et al.  Exploration of the ASCO and ESMO Value Frameworks for Antineoplastic Drugs. , 2017, Journal of oncology practice.

[20]  S. Bartelt,et al.  Patients with brain metastases: hope for recursive partitioning analysis (RPA) class 3. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[21]  S. Paek,et al.  Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: integrating with lung specific GPA score. , 2014, Lung cancer.

[22]  P. Levendag,et al.  Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. , 1999, International journal of radiation oncology, biology, physics.

[23]  N. Macdonald,et al.  The predictive value of pre-treatment inflammatory markers in advanced non-small-cell lung cancer. , 2010, Current oncology.

[24]  G. Qin,et al.  Comparison of the Glasgow Prognostic Score (GPS) and the modified Glasgow Prognostic Score (mGPS) in evaluating the prognosis of patients with operable and inoperable non-small cell lung cancer , 2016, Journal of Cancer Research and Clinical Oncology.

[25]  Christine M. Micheel,et al.  Beyond Histology: Translating Tumor Genotypes into Clinically Effective Targeted Therapies , 2014, Clinical Cancer Research.

[26]  Paul K J Han,et al.  Physicians' perceptions of the value of prognostic models: the benefits and risks of prognostic confidence , 2015, Health expectations : an international journal of public participation in health care and health policy.

[27]  C. Gridelli,et al.  Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials. , 2010, European journal of cancer.

[28]  Hushan Yang,et al.  Modeling the overall survival of patients with advanced‐stage non‐small cell lung cancer using data of routine laboratory tests , 2015, International journal of cancer.

[29]  Meihua Wang,et al.  A nomogram for individualized estimation of survival among patients with brain metastasis. , 2012, Neuro-oncology.

[30]  P. Ellis,et al.  An Evidence-Based Approach to the Use of Predictive Biomarkers in the Treatment of Non- Small Cell Lung Cancer (NSCLC) , 2011, Cancers.

[31]  D C McMillan,et al.  Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer , 2003, British Journal of Cancer.

[32]  M. Tsao,et al.  A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[33]  M. Socinski,et al.  Third-Generation Chemotherapy Agents in the Treatment of Advanced Non-small Cell Lung Cancer: A Meta-Analysis , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[34]  E. Vasile,et al.  Natural History of Non-Small-Cell Lung Cancer with Bone Metastases , 2015, Scientific Reports.

[35]  P. Lambin,et al.  Learning methods in radiation oncology ‘Rapid Learning health care in oncology’ – An approach towards decision support systems enabling customised radiotherapy’ q , 2013 .

[36]  J. Sculier.  Nonsmall cell lung cancer , 2013, European Respiratory Review.

[37]  D. Wajsbrot,et al.  Radiosurgery for brain metastases: a score index for predicting prognosis. , 2000, International journal of radiation oncology, biology, physics.

[38]  David W. Hosmer,et al.  Applied Logistic Regression , 1991 .

[39]  N. Macdonald,et al.  Montreal prognostic score: estimating survival of patients with non-small cell lung cancer using clinical biomarkers , 2013, British Journal of Cancer.

[40]  Yasuaki Tokuhashi,et al.  Scoring system for prediction of metastatic spine tumor prognosis. , 2014, World journal of orthopedics.

[41]  M. Ferrone,et al.  2015 Marshall Urist Young Investigator Award: Prognostication in Patients With Long Bone Metastases: Does a Boosting Algorithm Improve Survival Estimates? , 2015, Clinical orthopaedics and related research.

[42]  Bruno Vanderlinden,et al.  Radiosurgery for treatment of brain metastases: estimation of patient eligibility using three stratification systems. , 2004, International journal of radiation oncology, biology, physics.

[43]  D. Rades,et al.  Scoring systems to estimate intracerebral control and survival rates of patients irradiated for brain metastases. , 2011, International journal of radiation oncology, biology, physics.

[44]  M. Ahluwalia,et al.  Prognostic scores for brain metastasis patients: use in clinical practice and trial design. , 2015, Chinese clinical oncology.

[45]  L Gaspar,et al.  Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. , 1997, International journal of radiation oncology, biology, physics.

[46]  S. Senan,et al.  A statistical comparison of prognostic index systems for brain metastases after stereotactic radiosurgery or fractionated stereotactic radiation therapy. , 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).

[47]  Y. Higuchi,et al.  Subclassification of recursive partitioning analysis Class II patients with brain metastases treated radiosurgically. , 2012, International Journal of Radiation Oncology, Biology, Physics.

[48]  M. Mehta,et al.  Prognostic indices for brain metastases – usefulness and challenges , 2009, Radiation oncology.

[49]  Qinghua Zhou,et al.  Comparisons between the National Comprehensive Cancer Network (NCCN) non‐small‐cell lung cancer (NSCLC) Clinical Practice Guidelines (Chinese version), the NCCN original edition, and the European Society for Medical Oncology NSCLC Guidelines in 2009 , 2010, Thoracic cancer.

[50]  H. Matsuzaki,et al.  A revised scoring system for preoperative evaluation of metastatic spine tumor prognosis. , 2002, Spine.

[51]  Joshua T. Cohen,et al.  Measuring the Value of New Drugs: Validity and Reliability of 4 Value Assessment Frameworks in the Oncology Setting. , 2017, Journal of managed care & specialty pharmacy.

[52]  Yang Zhang,et al.  Validation of a clinical prognostic model in Chinese patients with metastatic and advanced pretreated non-small cell lung cancer treated with gefitinib , 2011, Medical oncology.

[53]  C. Nieder,et al.  Prognostic models predicting survival of patients with brain metastases: integration of lactate dehydrogenase, albumin and extracranial organ involvement. , 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).

[54]  A. Evans,et al.  Translating Clinical Research into Clinical Practice: Impact of Using Prediction Rules To Make Decisions , 2006, Annals of Internal Medicine.

[55]  L. Souhami,et al.  The Management of Brain Metastases in Non-Small Cell Lung Cancer , 2014, Front. Oncol..

[56]  B. Asselain,et al.  4-year mortality in patients with non-small-cell lung cancer: development and validation of a prognostic index. , 2006, The Lancet. Oncology.

[57]  G. Collins,et al.  Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies: The CHARMS Checklist , 2014, PLoS medicine.

[58]  J. Schiller,et al.  Prognostic Models to Predict Survival in Non–Small-Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[59]  D. Rades,et al.  A New Scoring System to Predicting the Survival of Patients Treated with Whole-Brain Radiotherapy for Brain Metastases , 2008, Strahlentherapie und Onkologie.

[60]  D. Rades,et al.  A new survival score for patients with brain metastases from non-small cell lung cancer , 2013, Strahlentherapie und Onkologie (Print).

[61]  C. Compton,et al.  Refining Prognosis in Lung Cancer: A Report on the Quality and Relevance of Clinical Prognostic Tools , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[62]  H. Cohen,et al.  Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups. , 2015, Lung cancer.

[63]  L. Seymour,et al.  A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[64]  C. McArdle,et al.  Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer , 2007, International Journal of Colorectal Disease.

[65]  R Sawaya,et al.  Benign reversible encephalopathy syndrome after bevacizumab therapy for metastatic ovarian cancer , 2014, Medical Oncology.

[66]  Y. Shibamoto,et al.  A new grading system focusing on neurological outcomes for brain metastases treated with stereotactic radiosurgery: the modified Basic Score for Brain Metastases. , 2014, Journal of neurosurgery.

[67]  L. Oñate-Ocaña,et al.  Association of Nutrition Parameters Including Bioelectrical Impedance and Systemic Inflammatory Response With Quality of Life and Prognosis in Patients With Advanced Non-Small-Cell Lung Cancer: A Prospective Study , 2012, Nutrition and cancer.